Digest Network Come funziona
Network
/
Società
Ta
Non verificato

Takeda Pharmaceutical Company Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

45 comunicati stampa

Guarda tutti i comunicati
02/03/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
19/02/2026
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
10/02/2026
Industria
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato azionario
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
22/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
05/01/2026
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
18/12/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
06/12/2025
Mercato del lavoro
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
07/11/2025
Eventi
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0
03/11/2025
Industria
HIV, AIDS e malattie autoimmuni
Farmaceutica
Salute
Medicina - Varie
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Fonte
Takeda Pharmaceutical Company Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0